Browse Items (3 total)

Results of the phase 2 LATTE study show that after 24 weeks of induction triple therapy, maintenance therapy with cabotegravir (a long-acting dolutegravir analogue) and rilpivirine led to virological suppression in 82% of patients, compared to 71 %…

Output Formats

atom, dcmes-xml, json, omeka-xml, rss2